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Abstract
Background: New animal models of chronic pulmonary hypertension in mice are needed. The
injection of monocrotaline is an established model of pulmonary hypertension in rats. The aim of
this study was to establish a murine model of pulmonary hypertension by injection of the active
metabolite, monocrotaline pyrrole.
Methods: Survival studies, computed tomographic scanning, histology, bronchoalveolar lavage
were performed, and arterial blood gases and hemodynamics were measured in animals which
received an intravenous injection of different doses of monocrotaline pyrrole.
Results: Monocrotaline pyrrole induced pulmonary hypertension in Sprague Dawley rats. When
injected into mice, monocrotaline pyrrole induced dose-dependant mortality in C57Bl6/N and
BALB/c mice (dose range 6–15 mg/kg bodyweight). At a dose of 10 mg/kg bodyweight, mice
developed a typical early-phase acute lung injury, characterized by lung edema, neutrophil influx,
hypoxemia and reduced lung compliance. In the late phase, monocrotaline pyrrole injection
resulted in limited lung fibrosis and no obvious pulmonary hypertension.
Conclusion:  Monocrotaline and monocrotaline pyrrole pneumotoxicity substantially differs
between the animal species.
Background
Idiopathic pulmonary arterial hypertension (IPAH) is a
severe disease characterized by elevated pulmonary blood
pressure and pathological changes in the lung. These
changes, such as endothelial injury, and the proliferation
and migration of pulmonary vascular smooth muscle
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cells, lead to a reduction in the lumenal area of pulmo-
nary vessels [1]. They are also accompanied by right ven-
tricular hypertrophy and end-stage heart failure [2].
Animal models are important tools for the study of the
pathogenic mechanisms of pulmonary hypertension
(PH), and for the development of novel therapeutic strat-
egies. Established models of PH include chronic exposure
to hypoxia, and subcutaneous or intraperitoneal applica-
tion of monocrotaline (MCT) or monocrotaline pyrrole
(MCTP) in different mammals [3]. Increased shear stress
by pneumonectomy [4], ductus arteriosus ligation [5,6] or
anastomosis of the systemic arterial to the pulmonary
arterial circulation [7,8] have been employed as alterna-
tive stimuli. Importantly, however, there are very few
mouse models of PH, despite the obvious value of being
able to manipulate the genetic background of mice.
Chronic exposure of mice to hypoxia is the most common
mouse model of PH. Under chronic hypoxic exposure,
pulmonary vascular remodeling occurs within weeks. This
remodeling process is characterized by de novo musculari-
zation of previously non-muscular precapillary vessels,
and right heart hypertrophy.
In transgenic mouse models, hypoxia has been repeatedly
used to unmask the protective or deteriorating effects of a
targeted gene. It has been shown that transient receptor
potential channel 6 (TRPC6) knockout mice are protected
against pulmonary vascular remodeling induced by
hypoxia [9]. Similarly, 5-lipoxygenase knockout animals
exhibit decreased vascular remodeling in response to
hypoxia [10]. Conversely, prostacyclin receptor knockout
mice [11] or mice over-expressing the 5-hydroxytryp-
tamine transporter [12] develop more severe pulmonary
hypertension. However, the nature of the remodeling dif-
fers between species, and it has been shown that mice kept
under chronic hypoxia develop less PH than do rats main-
tained under comparable conditions [13].
The most aggressive form of PH in any animal model is
induced by injection of MCT, which is extracted from
plants of the genus Crotalaria [14,15], into rats. Although
not completely understood, the proposed mechanism of
action includes activation of the crude MCT alkaloid to
the putative electrophile monocrotaline pyrrole (MCTP)
[16,17] in the liver, which causes endothelial injury in the
pulmonary vasculature with subsequent remodeling of
the precapillary vessels and progressive pulmonary hyper-
tension [18]. The limited opportunities to investigate
genetic contributions to the pathophysiology of the pul-
monary hypertension using this animal model highlight
the importance of mice as laboratory animals. However,
mice appear to be more resistant than rats to the effects of
MCT, and these mice do not develop PH to the same
degree. Injection or oral application of MCT to mice
causes liver damage [19], modest pulmonary fibrosis [20-
22] and immunotoxicity [23,24]. It has been proposed
that liver metabolism of MCT to MCTP by the cytochrome
P450 [25] system may differ between these species
[25,26]. To circumvent this, in vitro methods have been
developed to synthesize MCTP chemically [27], which is
then stable in dimethyl formamide (DMF). Intravenous
injection of the chemically-synthesized MCTP into the
right atrium induces pulmonary hypertension in dogs
[28,29].
The purpose of the present study was to investigate
whether injection of MCTP results in PH in the two differ-
ent mouse strains C57Bl/6 and Balb/c, and to characterize
the course of the disease. Parts of this study were previ-
ously reported in an abstract to European Respiratory
Society Conference 2006 [30].
Methods
Monocrotaline pyrrole synthesis
Monocrotaline pyrrole (MCTP) was chemically synthe-
sized according using the methodology of Mattocks et al
[27]. Briefly, 45 mg monocrotaline (Sigma-Aldrich, Ger-
many) was diluted in 5 ml pure chloroform and mixed in
a separation funnel with 45 mg o-chloranil (Fluka, Ger-
many) in 5 ml chloroform. The solution was gently
shaken and 0.5 ml of aqueous NaOH/NaBH4 (70:2; %:%)
was added, and the mixture was vigorously shaken for 10
s, resulting in a blue biphasic solution. The clear, organic
phase was separated and concentrated under vacuum. The
resulting white crystals were weighed and solved in DMF.
Thin layer chromatograms
Thin layer chromatograms were performed as described
elsewhere [27]. Briefly, MCT or MCTP were run on silica-
coated aluminium sheets (Merck, Germany) using light
petroleum (b.p. 60–80°C):acetone (1:1) as eluting agent.
Reaction with Ehrlich reagent results in a magenta color,
which indicates the presence of MCTP, while reaction
with o-chloranil followed by Ehrlich reagent detects both
MCT and MCTP.
Animals
Adult male C57Bl/6 or Balb/c mice (20–22 g body
weight) and Sprague Dawley rats (300–350 g body
weight) were obtained from Charles River Laboratories.
Animals were housed in an environmentally-controlled
animal facility for the duration of the experiment. Ani-
mals were provided with rodent chow and water ad lib-
rium. All experiments were performed according to the
institutional guidelines that comply with national and
international regulations.BMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25
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Experimental protocol
Three groups, each consisting of five adult male Sprague
Dawley rats randomly received s.c. injection of MCT (60
mg/kg) or i.v. injection of saline (0.5 ml) or MCTP (5 mg/
kg). Hemodynamic measurements and assessment of
right heart hypertrophy were made 28 days post MCT or
MCTP injection.
To investigate the toxicity and survival rate, groups of
eight C57Bl/6 and Balb/c mice received i.v. DMF (as vehi-
cle) or MCTP at a dose of 6, 8, 10 and 15 mg/kg body
weight. Hemodynamic measurements were made and
right heart hypertrophy assessed after 28 days. Further-
more, seven groups, each consisting of 10 C57Bl/6 mice,
received i.v. DMF or MCTP at a dose of 10 mg/kg body
weight. Mice were randomly assessed for lung compli-
ance, and cell counts in bronchoalveolar lavage fluid and
histological changes in the lung were measured 3, 7, 14,
21 and 28 days after MCTP injection. Another group of
five C57Bl/6 mice was i.v. injected with MCTP 10 mg/kg
and subjected to flat-panel computed tomography at 3, 7,
14, 21 and 28 days.
MCT and MCTP injection
Injection of rats with the MCT was performed as described
previously [31]. Control rats received subcutaneous
saline. For MCTP injection, mice or rats were anesthetized
by intra-peritoneal injection with ketamine/xylazine.
During the procedure, animals were placed on a heating
pad to maintain body temperature in the physiological
range. The jugular vein was surgically exposed, and MCTP
was injected intravenously according to the body weight
using a low volume syringe (Hammilton, Swiss) and a 30
G needle. The incision was sutured and local disinfection
was performed. Surgery was performed under aseptic con-
ditions. After surgery, mice received oral antibiotics
(Baytril® 1 ml/250 ml in drinking water).
Hemodynamic measurements
Hemodynamic measurements were performed in rats four
weeks after MCT or MCTP administration, as described
previously [31,32]. Mice were subjected to hemodynamic
measurements 3, 7, 14, 21 and 28 days after MCTP injec-
tion. Animals were deeply anaesthetized as previously
described [31,32], and the systemic arterial pressure (SAP)
was monitored by cannulating the left carotid artery using
a polyethylene cannula connected to a fluid-filled force
transducer. The right jugular vein was used for catheteriza-
tion of the right ventricle with a custom-made silicone
catheter.
Lung compliance measurement
Lung compliance was measured as described previously
[33]. Briefly, mice were anesthetized, tracheostomized
and ventilated with 6 ml/kg body weight using a pressure-
controlled ventilator.
Cell count in bronchoalveolar lavage fluid
After lung compliance measurements, BAL fluid (BALF)
was sampled. Briefly, three successive instillations of 0.5
ml phosphate-buffered saline/EDTA (1%) were per-
formed. The recovered BALF was centrifuged, the pellet
was resuspended in saline solution and the total cell
number was determined using a Neubauer chamber. For
differential cell-counts, samples from BALF were spun
onto a slide with a cytospin centrifuge (Shandon, Frank-
furt, Germany) and stained with May-Grünwald-Giemsa.
The relative numbers of each cell type were determined by
direct assessment under 200× microscopic magnification,
and expressed as a percentage of the total cell population
present in the BALF.
Tissue processing
After measurement of hemodynamic parameters, animals
were exsanguinated by opening the carotid artery and
blood samples were collected. The left lobe of the lung
was used to assess the lung wet/dry weight ratio measure-
ment. The right lung was flushed through the pulmonary
artery with saline, and fixed with a 2% formalin-based
solution through the pulmonary circulation, using a con-
stant pressure of 22 cm H2O. A counter pressure of 11 cm
H2O was used on the alveolar side during fixation, in
order to preserve the anatomical structure of the lung.
Lung lobes were embedded in parafin blocks, and serial
sections of 3 μm thickness were prepared and stained with
Hematoxylin-Eosin and Masson's trichrome.
Flat-panel Computed Tomography
The fpvCT is a novel high-resolution CT system developed
by General Electric (GE Global Research, Niskayuna, NY).
In contrast to clinical CT scanners, an amorphous silicon
flat-panel detector is irradiated by a cone-shaped X-ray
beam. Animals were anesthetized by intraperitoneal injec-
tion of a mixture containing ketamine (Ketavet 100 mg/
ml, Pharmacia & Upjohn) and xylazine (Rompun 2%,
Bayer AG) and mounted on a table, which was then
moved into the gantry bore during the scan, while the X-
ray tube and detector, mounted on a rotating gantry,
rotated around the table. The scan was performed in a
sequential rather than a helical mode. For our investiga-
tions, 120 kVp at 40 mA was used. The scanning time for
one rotation was 8 seconds, covering a field-of-view of 4.2
cm in the z-direction, sufficient for scanning the thorax of
one mouse. Projection images were reconstructed using a
cone-beam algorithm and an edge-defining reconstruc-
tion kernel [34,35]. Data can be reconstructed at arbitrary
voxel sizes, but 0.05 mm3 isotropic voxels were used for
this investigation. All data were transferred to an Advan-
tage Windows Workstation 4.1 (GE Health Care Europe,BMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25
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Buc, France) and processed with Volume Rendering soft-
ware.
Data analysis
All data are given as the mean ± SEM. Differences between
groups were assessed by ANOVA and Student-Newman-
Keuls post hoc test for multiple comparisons, with a prob-
ability value < 0.05 regarded as significant.
Results
Analysis of MCTP and MCTP-injection in rats
The chemically-synthesized MCTP was subjected to thin
layer chromatography (TLC) to evaluate the efficacy of
chemical synthesis and MCTP purity. This revealed that
the MCTP preparation obtained was pure (Figure 1A).
Subcutaneous injection of MCT in Sprague Dawley rats at
a dose of 60 mg/kg resulted in dramatic increase in right
ventricular systolic pressure (76.87 ± 4.87 versus 25.08 ±
1.35 for control, *p < 0.05) and severe right heart hyper-
trophy (0.64 ± 0.01 versus 0.30 ± 0.01 for control, *p <
0.05) after four weeks. The MCTP was dissolved in DMF
and injected intravenously into rats at a dose of 5 mg/kg.
After four weeks, this led to elevated right ventricular
systolic pressure (59.60 ± 2.93 versus 25.08 ± 1.35 for
control, *p < 0.05, compared to controls) and significant
right heart hypertrophy (0.47 ± 0.02 versus 0.30 ± 0.01,
*p < 0.05, compared to controls). (Figure 1B and 1C). The
effects induced by MCT and MCTP on right ventricular
pressure and right heart hypertrophy were lower after
MCTP injection than after MCT injection.
Efficacy of monocrotaline pyrrole (MCTP) synthesis (A) and impact of MCTP and monocrotaline (MCT) on right heart hyper- trophy (B) and pulmonary pressure (C) in Sprague Dawley rats Figure 1
Efficacy of monocrotaline pyrrole (MCTP) synthesis (A) and impact of MCTP and monocrotaline (MCT) on 
right heart hypertrophy (B) and pulmonary pressure (C) in Sprague Dawley rats. Quality and purity of the final 
product MCTP were assessed by thin layer chromatograms (A). Rats were either subcutaneously injected with monocrotaline 
(60 mg/kg body weight) or intravenously with monocrotaline pyrrole (5 mg/kg body weight) and its vehicle DMF. Right ventri-
cle pressure was measured four weeks after MCT or MCTP by right heart catheterization in anaesthetized animals. Right heart 
hypertrophy was assessed by calculating right ventricle/left ventricle plus septum (RV/LV+S) weight ratio. *, p < 0.05 versus 
DMF group.BMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25
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Injection of MCTP in mice: mortality
The MCTP was intravenously injected into C57Bl/6 mice
at different doses. The MCTP had dose-dependent, toxic
effects (Figure 2A). Similar effects were observed when
mice with a Balb/c genetic background were injected with
different doses of MCTP (Figure 2B). Interestingly, mortal-
ity was observed only between day 1 and day 4. The
MCTP-injected animals exhibited decreased body weight,
dyspnea, and developed lung edema and pronounced
pleurisy. We further investigated in detail the lung
changes in C57Bl/6 mice in the group treated with 10 mg/
kg body weight, which exhibited a mortality rate of
approximately 20%.
Injection of MCTP in mice: histology and lung function
Hematoxylin-Eosin staining of the lungs from mice
treated with 10 mg/kg body weight at different time
points (Figure 3) in the early phase (three days after MCTP
injection) revealed diffuse alveolar damage, alveolar exu-
dates, interstitial edema with thickening of the alveolar
septae, perivascular edema, and inflammatory cellular
infiltrates. Lung edema was still present at seven days after
treatment, but was resorbed by days 14–21. At day 28, no
lung edema was apparent, but some areas of the lung
developed fibrotic foci, starting on day 7 and culminating
on day 28. These changes were accompanied by cellular
inflammatory infiltrates, where lymphocytes were the
prominent inflammatory cells present in the late phase,
while granulocytes were prominent in the early phase. The
vascular smooth muscle layer was not obviously affected
at any of the time-points investigated, but consistent
adventitial and perivascular edema was seen in at early-
time points after MCTP injection (Figure 3). Fibrotic
changes in mice injected with MCTP were assessed by
Masson's trichrome staining and lung compliance meas-
urements. In the early phase, lung compliance measure-
ments revealed a dramatic drop (0.090 ± 0.0005 ml/kPa
in MCTP-treated animals versus 0.153 ± 0.0067 ml/kPa in
vehicle-treated animals, p < 0.05) of the lung function
(Figure 4) which, together with structural changes, indi-
cated a massive reduction in the alveolar space and a
reduction in parenchymal elasticity due to parenchymal
and alveolar edema. In the late phase (28 days), lung
compliance was similar to normal values, and lung edema
disappeared, but localized limited fibrotic foci had
formed. Interestingly, small pulmonary arteries did not
show obvious signs of muscularization even in the
fibrotic areas which were most likely the more strongly
affected areas of the lung (Figure 5). Another assessment
of lung edema is lung wet/dry weight ratio. This assess-
ment revealed an increased ratio in the early phase for
mice injected with MCTP in comparison to mice injected
with vehicle (DMF) alone (Figure 6A).
Injection of MCTP in mice: BAL fluid
In order to confirm and investigate in greater detail the
immune reaction to MCT administration, inflammatory
cell numbers in BALF were assessed. Three days after
MCTP injection, increased numbers of granulocytes
(15.25 ± 7.68% of total cells in the MCTP-treated group
versus  0.33 ± 0.33% of total cells in the DMF-treated
group) were present in BALF (Figure 7C), revealing acute
lung inflammation. This phenomenon was reduced over
time, up to day 28 (0.00 ± 0.00%) and, interestingly, was
accompanied by an increased number of lymphocytes
(10.75 ± 2.75% from total cells at day 28) (Figure 7D).
Monocyte numbers did not change significantly over time
after intravenous MCTP injection (Figure 7A, B, C and
7D).
Injection of MCTP in mice: hemodynamics and gas 
exchange
Interestingly, gas exchange was affected by MCTP admin-
istration (Figure 6B). Arterial oxygenation (pO2) meas-
ured in blood collected from the carotid artery was
significantly lower in MCTP-treated animals (65.06 ±
2.58) when compared to vehicle-treated animals (92.6 ±
9.6, p < 0.05)
When MCTP was intravenously injected into Sprague
Dawley rats it induced elevated pulmonary arterial pres-
sure and right heart hypertrophy, indicating pulmonary
hypertension. We investigated whether the MCTP injury
induces pulmonary hypertension when injected intrave-
nously into mice. Right heart hypertrophy was assessed by
right ventricle per left ventricle plus septum weight ratio
(RV/(LV+S)). Before measuring RV/(LV+S), heart tissues
were dried for one week at room temperature in order to
avoid false-positive results due to heart edema. Pulmo-
nary pressure was measured as right ventricular systolic
pressure by right heart catheterization in anaesthetized
animals. As depicted in Figure 8A, 28 days after MCTP
injection, the pulmonary pressure did not vary signifi-
cantly for animals injected with different MCTP doses
26.6 ± 3.9 (for 6 mg MCTP/kg), 25.9 ± 2.3 (for 8 mg
MCTP/kg) and 27.0 ± 4.2 (for 10 mg MCTP/kg) versus ani-
mals injected with vehicle (25.8 ± 2.0 mmHg). These
results are in line with the right heart hypertrophy assess-
ments (Figure 8B) 0.264 ± 0.026 (for 6 mg MCTP/kg),
0.256 ± 0.032 (for 8 mg MCTP/kg) and 0.275 ± 0.021 (for
10 mg MCTP/kg) versus DMF-injected animals (0.271 ±
0.009). Pulmonary artery pressure was investigated at 3, 7,
14, 21 and 28 days after MCTP injection at a dose of 10
mg/kg body weight. Although a small elevation was
observed in MCTP-treated animals (26.8 ± 1.3, 28.0 ± 1.2,
25.0 ± 1.1, 30.9 ± 0.9 and 26.3 ± 0.8 mmHg at 3, 7, 14, 21
and 28 days respectively), it did not differ significantly
when compared with vehicle-treated animals (26.7 ± 0.7
mmHg) (Figure 9A). Similarly, small but not statisticallyBMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25
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Dose-dependant survival rate of mice treated with monocrotaline pyrrole Figure 2
Dose-dependant survival rate of mice treated with monocrotaline pyrrole. C57Bl 6 (A) and Balb/c (B) mice were 
intravenously injected with different doses of monocrotaline pyrrole. Mice (n = 10 each group) were intravenously injected 
with monocrotaline pyrrole (MCTP) in doses varying from 6 to 15 mg per kilogram body weight or its vehicle (DMF). Survival 
was observed for the next 28 days after injection.BMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25
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significant changes in the RV/LV+S heart ratio were
observed: 0.295 ± 0.010, 0.278 ± 0.006, 0.295 ± 0.012,
0.326 ± 0.014 and 0.277 ± 0.006 for 3, 7, 14, 21 and 28
days, respectively, after MCTP injection, versus  0.261 ±
0.006 for DMF injected animals (Figure 9B).
Injection of MCTP in mice: Computer tomography
In order to better understand and demonstrate the
changes induced by intravenous MCTP injection into
mice, mice were subjected to Flat-panel Volumetric Com-
puter Tomography (VCT) before, and at different time
points after, MCTP injection. As illustrated in Figure 10, in
comparison with the initial lung structure, after MCTP
injection the lung presented in the early phase increased,
and exhibited a homogenous opacity indicating lung
edema. This lung opacity diminished over time. In the late
phase, at day 28, some heterogeneous lung opacities were
still present, probably indicating fibrotic changes.
Discussion
The aim of this study was to establish a new murine model
of pulmonary hypertension by injection of monocrota-
line (MCT), a plant alkaloid of Crotalaria spectabilis. In
rats, the subcutaneous injection of MCT causes endothe-
lial injury in the pulmonary vasculature with subsequent
remodeling of the precapillary vessels (medial thickening,
de novo muscularization of small pulmonary arterioles).
Due to this mimicry of clinical pulmonary arterial hyper-
tension, the rat MCT model has repeatedly been
employed for investigating acute hemodynamic and gas
exchange effects of vasodilators and the chronic anti-
remodeling effects of anti-inflammatory and anti-prolifer-
ative agents [31,32,36]. Reproducible induction of severe,
progressive pulmonary hypertension in response to MCT
has been reported [37,38]. Although MCT has been used
for the past five decades, the mechanism of action is still
not clear. The proposed mechanism of action includes
activation of MCT by liver cytochromes to a putative elec-
trophile monocrotaline pyrrole (MCTP) which is highly
reactive and possesses a short half life of 3–4 s in aqueous
solution [39]. In the blood, it might circulate associated
with red blood cells which stabilize and transport it to the
active site, for example, the lung endothelium.
Previous studies have reported that the administration of
MCT in mice in different forms, such as from the Crota-
laria spectabilis plant [40], by the oral administration of
crude alkaloid [21,23,26] or subcutaneous injections
[20,22,41,42]. Vascular and lung parenchymal inflamma-
tion, lung edema, moderate lung fibrosis and minor right
heart hypertrophy were reported in these studies. Most of
these studies have suggested that mice are comparatively
deficient in the liver enzymes that convert MCT to its
active metabolites [20,25,41].
As mice are highly attractive for pulmonary hypertension
research due to the possibility of using genetically-engi-
neered animals, multiple groups have attempted to estab-
lish new mouse models of pulmonary hypertension
[21,22,41,42]. We chemically dehydrated MCT to MCTP
Monocrotaline pyrrole-induced structural changes in lungs from C57Bl 6 mice and Sprague Dawley rats Figure 3
Monocrotaline pyrrole-induced structural changes in lungs from C57Bl 6 mice and Sprague Dawley rats. Repre-
sentative histological pictures correspond to C57Bl 6 mice injected with DMF (vehicle) 28 days (A and G), MCTP 3 days (B and 
H), MCTP 7 days (C and I) and MCTP 28 days (D and J). Structural changes in rat lungs were assessed at 28 days after vehicle 
(E and K) or MCTP injection (F and L) Haematoxylin-Eosin staining is shown. Arrows indicate small pulmonary arteries. Scale 
bar = 50 μm.BMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25
Page 8 of 15
(page number not for citation purposes)
Effect of monocrotaline pyrrole on lung compliance Figure 4
Effect of monocrotaline pyrrole on lung compliance. C57Bl 6 mice were intravenously injected with MCTP (10 mg/kg 
body weight) or vehicle. Lung compliance was measured at 3, 7 and 21 days. *, p < 0.05 versus control or DMF-injected ani-
mals.
Fibrotic changes in C57Bl 6 mice after monocrotaline pyrrole injection Figure 5
Fibrotic changes in C57Bl 6 mice after monocrotaline pyrrole injection. Mice received intravenous injection of 
MCTP 10 mg/kg body weight or DMF as vehicle. Masson's trichrome staining was performed on serial sections from Figure 3. 
Scale bar = 50 μm. Black arrows indicate small pulmonary arteries, red arrows indicate fibrotic changes.BMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25
Page 9 of 15
(page number not for citation purposes)
Effect of monocrotaline pyrrole on arterial pO2 and lung edema Figure 6
Effect of monocrotaline pyrrole on arterial pO2 and lung edema. Lung wet to dry weight ratio (A) and Arterial pO2 
(B) were measured in C57Bl 6 mice at 3, 7 and 28 days after MCTP or vehicle (DMF) injection. *, p < 0.05 versus control or 
DMF-injected animals.BMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25
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Lung inflammatory changes in C57Bl 6 mice after monocrotaline pyrrole injection Figure 7
Lung inflammatory changes in C57Bl 6 mice after monocrotaline pyrrole injection. C57Bl 6 mice intravenously 
received MCTP (10 mg/kg body weight) or its vehicle (DMF). BALF was obtained after 3, 7, 14, 21 and 28 days. The inflamma-
tory cellular profile in BALF was assessed as the total cell number (A) and the percentage of total cells of macrophages (B), 
granulocytes (C) and lymphocytes (D).
according to a methods of Mattocks [27] and injected dif-
ferent doses intravenously into two different mouse
strains (C57Bl 6 and BALB/c). Thin layer chromatograms
confirmed the purity of chemically-synthesized MCTP. In
addition, a positive control experiment included the injec-
tion of the synthesized MCTP into rats. This confirms
MCTP as being the active metabolite of MCT, and demon-
strates the efficacy of chemical synthesis. The difference in
the degree of pulmonary hypertension induced by MCTP
and MCT might correlate with the different bioavailabil-
ity, and dose differences (5 mg/kg for MCTP versus 60 mg/
kg for MCT). When injected intravenously, MCTP led to
dose-dependant mortality of both mouse strains within
the first week due to dyspnoea, pleural liquid accumula-
tion, lung edema and severe infiltration of inflammatory
cells into lung interstitium. Those animals which survived
exhibited similar signs and symptoms including minor
elevation of pulmonary pressure and right heart hypertro-
phy which was not significant compared to the control
animals. A slight increase in pulmonary artery pressure
was present in the early phase after MCTP administration
and was not sustained or progressive. This phenomenon
may be attributed to massive lung injury and inflamma-
tion which is usually associated with local cytokine and
other mediator release, for example, of TNF or thrombox-
ane [43,44]. In this regard, Molteni et al reported dysregu-
lation of angiotensin converting enzyme, plasminogen
activator and prostacyclin (PGI2) after MCT injection in
mice [21]. Histopathological changes in the lungs of mice
injected with MCTP consisted in the early phase of
perivascular and interstitial lung edema and diffuse alveo-
lar damage with alveolar hyaline membranes and inflam-
matory cell infiltration. The cellular profile in the
bronchoalveolar lavage fluid demonstrated the significantBMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25
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Parameters of pulmonary hypertension in C57Bl 6 mice 28 days after injection with monocrotaline pyrrole in different doses Figure 8
Parameters of pulmonary hypertension in C57Bl 6 mice 28 days after injection with monocrotaline pyrrole in 
different doses. Right Ventricular Systolic Pressure (A) and Right Ventricular Hypertrophy as the Futton index (B) is given.BMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25
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Right ventricular systolic pressure (RVSP) (A) and right ventricular hypertrophy (RV/LV+S) (B) of C57Bl 6 mice injected with  MCTP 10 mg/kg body weight Figure 9
Right ventricular systolic pressure (RVSP) (A) and right ventricular hypertrophy (RV/LV+S) (B) of C57Bl 6 
mice injected with MCTP 10 mg/kg body weight. Pulmonary hypertension parameters were measured at different time 
points: 3, 7, 14, 21 and 28 days.BMC Pulmonary Medicine 2008, 8:25 http://www.biomedcentral.com/1471-2466/8/25
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Lung changes in C57Bl 6 mice injected with monocrotaline pyrrole at different time points assessed by Flat-panel Volumetric  Computed Tomography (VCT) Figure 10
Lung changes in C57Bl 6 mice injected with monocrotaline pyrrole at different time points assessed by Flat-
panel Volumetric Computed Tomography (VCT).
increase in granulocytes which is a characteristic feature of
acute respiratory distress syndrome [45,46]. The above-
mentioned histopathological changes, together with the
inflammatory syndrome, are hallmarks of acute lung
injury. The initial inflammation and alveolar damage was
followed in the later phase by moderate localized lung
fibrosis. Lung compliance decreased significantly only in
the early time points due to fluid accumulation. Interest-
ingly, these animals seem to recover over time in terms of
lung compliance, exhibiting similar values at 28 days to
the control animals. Histopathological changes assessed
by Haematoxylin-Eosin and Masson's trichrome staining
revealed obvious fibrotic changes.
Similar changes have been reported by previous studies in
which MCT was administered in different forms. A major
objective of this study was to investigate whether MCTP
induces pulmonary hypertension in mice. We carefully
investigated the physiological and histological parameters
of pulmonary hypertension in these animals. Pathologi-
cally, these animals presented with a pseudo-wall-thick-
ness of small pulmonary arteries induced by adventitial
and perivascular edema, but there was no obvious sign of
muscularization or neo-muscularization of these vessels.
Right ventricular systolic pressure measured by right heart
catheterization in anaesthetized animals 28 days after
MCTP injection was slightly elevated. However, this did
not reach statistically significant levels in any of the
groups injected with different doses. This observation is
consistent with the assessment of right ventricular hyper-
trophy and histopathological changes reported by Hay-
ashi et al [22]. In fact, small pulmonary capillary
hypertension is one of the physiological abnormalities of
the acute respiratory distress syndrome [47]. Recently,
Raoul  et al. reported elevated pulmonary pressure and
right heart hypertrophy in mice 15 days after MCTP injec-
tion into the tail vein [48]. Although we used an appropri-
ate and even double the dose of MCTP reported in that
study, our study did not reveal significant differences in
pulmonary hypertension-related parameters which may
be dependant on the mouse strain or the MCTP synthesis.
However, considering the importance of a mouse model
of pulmonary hypertension, numerous research groups
will experiment with different technical approaches which
might prove successful. Our findings demonstrate that
interspecies differences in response to MCT and lung dis-
eases are not limited to the liver metabolism of these alka-
loids. Future experiments assessing mouse and rat
endothelial cells in response to MCTP might reveal the
basis of the interspecies variability. A technical limitation
of the study might be related directly to the MCTP appli-
cation: a bolus injection of MCTP versus slow release after
subcutaneous MCT injection. However, bolus injection of
MCTP in rats results in pulmonary changes which consist-
ently differ from those induced in mice.
Conclusion
To conclude, this study reports pathological pulmonary
changes induced by an application of the putative elec-
trophile MCTP in mice. Administration of MCTP in mice
and rats results in acute lung injury. In rats, but not in
mice, it ultimately leads to severe and progressive pulmo-
nary hypertension. To our knowledge, this is the first
study to report and characterize an animal model of acute
lung injury induced by monocrotaline pyrrole in mice.
Thus, MCTP injection in mice may be a valuable animal
model to investigate both the efficacy of new therapies for
acute respiratory failure and fibrotic repair mechanisms.
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